The Caring Ambassadors Program provides this website to help you and your loved ones understand your disease
and some of the healthcare option available to you.
Our three main methods to fight lung cancer are to Empower patients and providers with access to free educational materials, and resources; to Educate communities about the importance of screening and to share current information with patients and their families; and to Advocate for access to screening and treatment for lung cancer for all communities. Knowledge empowers you to ask the necessary questions to become your own best advocate. When your questions have been asked and answered, you and your healthcare providers will be in the best possible situation to determine the best treatment approach for you.
Caring Ambassadors has released Lung Cancer Choices 3rd Edition, an amazing resource for those diagnosed with lung cancer.
Are you a Caregiver?
Caregiver Choices, a resource for all those who find themselves in the role of caregiver for someone who has been diagnosed with lung cancer.
Week Ending December 10, 2018
Lung Cancer and the Young Adult Nonsmoker
“When it comes to lung cancer, recent statistics published by the National Cancer Institute show progress in the right direction.”
Researchers extend effectiveness of immunotherapy to more lung cancer patients
“Immunotherapy, the strategy for triggering the patient’s own immune system to attack cancer, is proving effective for more tumour types, although to varying degrees. In lung cancer, immunotherapy had proven to extend survival rates for only some variants of the disease.”
A newly discovered marker could allow quick diagnosis and lung cancer treatment
“An exciting study published in Science Translational Medicine has identified a novel protein which could aid in early diagnosis and lung cancer treatment.”
FDA approves Genentech drug for lung cancer
“Genentech, a member of the Roche Group, on Thursday said the U.S. Food and Drug Administration approved Tecentriq and chemotherapy for some patients with a certain type of lung cancer.”
Roche’s lung cancer combo treatment wins FDA approval
“Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq (atezolizumab) immunotherapy in combination with Avastin (bevacizumab) and chemotherapy won US Food and Drug Administration approval as a first-line treatment for a type of lung cancer.”